Valneva SE ADR (VALN) — Titan Protect Analysis

VALN

Valneva SE ADR

Healthcare · ·

$5.48

Data: 2026-06-03

✓ ETHICAL PASS

NONE MOAT

LIMITED

Data Confidence: 0.0%

Key Metrics

How this company measures up on the fundamentals that matter

Market Cap

$526M

Total market value of the company

Trailing P/E

N/A

Forward P/E

5.34

Based on estimated future earnings — lower means cheaper

Rev Growth

-37.2%

Year-over-year revenue change

Profit Margin

-88.3%

How much profit the company keeps from each dollar of revenue

ROE

-109.6%

Return on equity — how efficiently it uses shareholder money

Analyst Target

$13.00

+137% from current price — median analyst estimate

Recommendation

NONE

Consensus view from 4 analysts covering this stock

About Valneva SE ADR

Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; and IXCHIQ/ VLA1553, a single-dose, live-a

https://valneva.com

Country: France Employees: 674 Industry: Biotechnology

Ethical Screening

Five compliance checks based on AAOIFI standards — all must pass for ethical clearance

Business Activity

PASS

Core business does not involve prohibited activities

Debt Ratio

0.0% PENDING

Debt must be below 33% of total assets

Cash Ratio

0.0% PENDING

Interest-bearing cash below 33% of assets

Receivables

0.0% PENDING

Receivables below 49% of assets

Revenue Purity

0.0% PENDING

Non-compliant revenue below 5% — any excess requires purification

Quantitative Intelligence

Statistical analysis of price behaviour, risk, and market regime — independent of fundamental data

Regime

MARKUP

Price trending up with increasing momentum

Sharpe Ratio

0.068

Positive but modest risk-adjusted returns

Kelly Fraction

-0.0103

No positive edge detected — the data suggests staying out

Calmar Ratio

-0.325

Drawdown risk outweighs the returns — higher risk profile

Annual Return

-18.7%

Historical annualised return based on price data

Max Drawdown

-57.6%

Largest peak-to-trough decline — the worst it has been

HMM State

SIDEWAYS

Price consolidating — no clear directional bias

Days in State

How long the current regime has persisted — longer means more stable

Market Data

Trading characteristics and market positioning

Beta

N/A

52W High

$12.25

55% below the year high

52W Low

$5.06

8% above the year low

Avg Volume

92,765

Average daily shares traded — higher means easier to buy and sell

Short Ratio

1.9

Days it would take all short sellers to cover — higher means more crowded

Short % Float

N/A

Div Yield

N/A

Annual dividend as a percentage of the share price

EPS (TTM)

$-1.86

Earnings per share over the last 12 months

Financial Health

Balance sheet strength and cash generation — the foundation of long-term value

Debt/Equity

273.15

Heavy leverage — higher financial risk if revenues decline

Current Ratio

N/A

Quick Ratio

N/A

Like current ratio but excludes inventory — stricter test

Gross Margin

-25.1%

Revenue left after cost of goods — higher means pricing power

Operating Margin

-76.7%

Profit from core operations before interest and tax

Free Cash Flow

$-31,007,750

Negative — the business is spending more than it generates

Revenue (TTM)

$156M

Total revenue over the last 12 months

Net Income

$-138,032,992

Loss-making — spending exceeds revenue after all costs

Analyst Coverage

Analysts

Target High

$18.00

Target Median

$13.00

Target Low

$4.80

Explore the Ethical Screener View Track Record

Data sourced from public filings and market feeds. Not financial advice. Updated: 2026-06-03

Before you go